StockTipsArenaBeta

BUY CORONA Remedies Limited — MarketSmith India

BUYCORONA Remedies Limited
CORONA Remedies share price target & all analyst calls

byMarketSmith IndiaHorizon: 1–3 months4 Nov 2026via LiveMint Buy-or-Sell (topic)

Entry₹2,271.7Inferred
Target₹2,900
Total upside +27.66%
Stop loss₹2,088-8.09% risk
CMP₹2,441.11d ago
Active+7.46%+18.80%upside left 3 mo left
Follow MarketSmith India for new calls(13% target hit, 53 closed calls)Get alertsWatch CORONA for new buy/sell callsGet alertsSee 73 other Short-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 7 Nov, 5:28 pm IST
5 supporting1 opposing
Supports the BUY call (5)

MACD above its signal line — bullish momentum

Technicals · macd·7 Nov · today

Corona Remedies reported Q2 FY27 revenue of 441.2 crore, a 22.2% year-on-year increase, and EBITDA of 96 crore, a 22.3% increase. The company also received ANVISA GMP certification for its Bhayla faci

BSE · Company Update·30 Oct · 1w ago

(opens in new tab)

CORONA Remedies reported a 22.2% year-on-year revenue growth for Q2 FY27, with net profit reaching Rs 60.18 crore, driven by strong performance in its chronic and semi-chronic portfolios.

NSE · Outcome of Board Meeting·30 Oct · 1w ago

(opens in new tab)

Corona Remedies reported Q2 FY27 revenue of Rs 441.2 crore, a 22.2% year-on-year growth, and net profit of Rs 60.3 crore, a 15.3% year-on-year increase.

BSE · Board Meeting·30 Oct · 1w ago

(opens in new tab)

The company received GMP compliance certification from the Brazilian Health Regulatory Agency (ANVISA).

BSE · Company Update·22 Oct · 2w ago

(opens in new tab)
Neutral / worth noting (0)

Nothing found in this tip’s window yet.

Weighs against the BUY call (1)

RSI at 84 — overbought territory

Technicals · rsi·7 Nov · today

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on CORONA Remedies

All analyst calls on CORONA Remedies

More from MarketSmith India

Every call and its outcome